Because K391 and K477 SUMO sites are required for SENP1-regulated HIF-1α deSUMOylation, we wondered whether mutations in the SUMO site in HIF-1α would prevent the effect of CLDN6 overexpression in breast cancer cells. Here, CLDN6 is linked to breast cancer.